Clinical Trials
134
Active:1
Completed:116
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:70
Phase 2:7
+3 more phases
Drug Approvals
3
PHILIPPINES:3
Clinical Trials
Distribution across different clinical trial phases (109 trials with phase data)• Click on a phase to view related trials
Phase 1
70 (64.2%)Phase 3
22 (20.2%)Phase 2
7 (6.4%)Phase 4
6 (5.5%)Not Applicable
3 (2.8%)Early Phase 1
1 (0.9%)A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Not Applicable
Recruiting
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mgDrug: Metformin HCl 1000 mg
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT07083388
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
Not Applicable
Recruiting
- Conditions
- Diabete Mellitus
- Interventions
- Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mgDrug: Metformin HCl 1000 mg
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT07083401
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT07069335
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa District, Korea, Republic of
A Phase IV Clinical Study to Compared the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes
Phase 4
Not yet recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 204
- Registration Number
- NCT06972732
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06890299
- Locations
- 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 27
- Next
News
No news found